-
平臺編號：bio-69279
-
國際編號：CRL-2267?
-
細胞信息： BE(2)-M17
-
規(guī)格：Frozen
-
用途：ATCC原裝細胞
-
服務費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
BE(2)-M17
器官來源：大腦
數(shù)量：大量
生長狀態(tài)：貼壁生長
年限：2 years
細胞形態(tài)：神經(jīng)母細胞
是否是腫瘤細胞：1
物種來源：人
ATCC Number：CRL-2267?
運輸方式：凍存運輸
相關疾?。荷窠?jīng)母細胞瘤
規(guī)格：48T Designations: BE(2)-M17
Depositors: ?JL Biedler
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens
Morphology:neuroblast
Source: Organ: brain
Disease: neuroblastoma
Derived from metastatic site: bone marrow
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: Note: BE(2)-M17 was deposited at the ATCC by June L. Biedler, Memorial Sloan-Kettering Cancer Center. BE(2)-M17 is distributed for academic research purposes only. Memorial Sloan-Kettering releases the line subject to the following: 1.)BE(2)-M17 or its products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of BE(2)-M17 including any use by a for-profit entity must first be negotiated with Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.
Applications:transfection host (Roche Transfection Reagents )
DNA Profile (STR):Amelogenin: X
CSF1PO: 10
D13S317: 11
D16S539: 11
D5S818: 12
D7S820: 9,10
THO1: 6
TPOX: 8,11
vWA: 18
Age: 2 years
Gender: male
Comments:BE(2)-M17 is a clone of the SK-N-BE(2) neuroblastoma cell line (see ATCC CRL-2271 ) that was established in November of 1972 from a bone marrow biopsy taken from a 2 year old male with disseminated neuroblastoma.
After repeated courses of chemotherapy and radiotherapy.
BE(2)-M17 cells have a reported saturation density of greater than 1 X 10 exp6 cells/sq cm.
The cells grow as multilayering, neuroblastic cells with occasionally long neuritic processes.
As cultures age, cells will aggregate and float.
Propagation: ATCC complete growth medium: The base medium for this cell line is a 1:1 mixture of ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003, and F12 Medium. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:20 to 1:50 is recommended
Medium Renewal: Every 4 to 7 days
Remove spent medium, add fresh 0.25% trypsin, 0.03% EDTA solution, rinse and remove trypsin.
Add fresh trypsin solution (1 to 2 ml) and let the culture sit at room temperature (or at 37C) until the cells detach.
Add fresh medium, aspirate and dispense into new flasks.
Preservation: Culture medium, 95%; DMSO, 5%
Doubling Time: 20 to 24 hrs
Related Products:recommended serum:ATCC 30-2020
數(shù)量：大量
生長狀態(tài)：貼壁生長
年限：2 years
細胞形態(tài)：神經(jīng)母細胞
是否是腫瘤細胞：1
物種來源：人
ATCC Number：CRL-2267?
運輸方式：凍存運輸
相關疾?。荷窠?jīng)母細胞瘤
規(guī)格：48T Designations: BE(2)-M17
Depositors: ?JL Biedler
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens
Morphology:neuroblast
Source: Organ: brain
Disease: neuroblastoma
Derived from metastatic site: bone marrow
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: Note: BE(2)-M17 was deposited at the ATCC by June L. Biedler, Memorial Sloan-Kettering Cancer Center. BE(2)-M17 is distributed for academic research purposes only. Memorial Sloan-Kettering releases the line subject to the following: 1.)BE(2)-M17 or its products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of BE(2)-M17 including any use by a for-profit entity must first be negotiated with Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.
Applications:transfection host (Roche Transfection Reagents )
DNA Profile (STR):Amelogenin: X
CSF1PO: 10
D13S317: 11
D16S539: 11
D5S818: 12
D7S820: 9,10
THO1: 6
TPOX: 8,11
vWA: 18
Age: 2 years
Gender: male
Comments:BE(2)-M17 is a clone of the SK-N-BE(2) neuroblastoma cell line (see ATCC CRL-2271 ) that was established in November of 1972 from a bone marrow biopsy taken from a 2 year old male with disseminated neuroblastoma.
After repeated courses of chemotherapy and radiotherapy.
BE(2)-M17 cells have a reported saturation density of greater than 1 X 10 exp6 cells/sq cm.
The cells grow as multilayering, neuroblastic cells with occasionally long neuritic processes.
As cultures age, cells will aggregate and float.
Propagation: ATCC complete growth medium: The base medium for this cell line is a 1:1 mixture of ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003, and F12 Medium. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:20 to 1:50 is recommended
Medium Renewal: Every 4 to 7 days
Remove spent medium, add fresh 0.25% trypsin, 0.03% EDTA solution, rinse and remove trypsin.
Add fresh trypsin solution (1 to 2 ml) and let the culture sit at room temperature (or at 37C) until the cells detach.
Add fresh medium, aspirate and dispense into new flasks.
Preservation: Culture medium, 95%; DMSO, 5%
Doubling Time: 20 to 24 hrs
Related Products:recommended serum:ATCC 30-2020
